PTPRS De-clustering Agent for Rheumatoid Arthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for rheumatoid arthritis (RA) do not effectively target fibroblast-like synoviocytes (FLS), which are key players in inflammation and joint destruction, due to limited understanding of the role of protein tyrosine phosphatases (PTPs) and receptor protein tyrosine phosphatases (RPTPs) in mediating FLS behavior.
Innovation Solution
A non-enzymatic recombinant protein comprising the amino acid sequence of the extracellular domain of PTPRS, including immunoglobulin-like domains 1 and 2, is used as a PTPRS de-clustering agent to treat arthritis by modulating the extracellular matrix and inhibiting FLS invasiveness and migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for rheumatoid arthritis, then general immune suppression is achieved, but fibroblast-like synoviocytes are not effectively targeted
Solution Approach 1:
The patent uses anti-PTPRS antibodies as intermediary agents that specifically bind to PTPRS proteins on FLS surfaces, enabling selective targeting of fibroblast-like synoviocytes without affecting other immune cells. This mediator approach allows precise delivery of therapeutic effect to the intended cell type, resolving the contradiction between general immune suppression and selective FLS targeting.
2Object-affected harmful factors
If PTPRS clustering is maintained, then FLS growth and invasiveness are promoted, but arthritis severity increases
Solution Approach 1:
The patent extracts or removes the clustered PTPRS proteins from the FLS surface using anti-PTPRS antibodies that bind to and internalize these proteins. By taking out the clustered PTPRS complexes, the therapy eliminates the signaling pathways that promote FLS growth and invasiveness, thereby reducing arthritis severity while maintaining control over FLS behavior through specific molecular targeting.
3Reliability
If more PTPRS de-clustering agents are developed, then FLS migration is better inhibited, but device complexity increases
Solution Approach 1:
The patent uses simplified antibody copies or fragments (such as Fab fragments or single-chain antibodies) that replicate the function of full-length anti-PTPRS antibodies. These copied therapeutic agents maintain the ability to bind and de-cluster PTPRS proteins while being structurally simpler and easier to produce, thus inhibiting FLS migration effectively without increasing overall therapeutic complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PTPRS de-clustering agent effectively reduces the severity of arthritis by disrupting the clustering of PTPRS proteins, thereby inhibiting FLS invasiveness and migration, and ameliorating joint damage in mouse models of RA.
Implementation Method 1
The PTPRS de-clustering agent effectively reduces the severity of arthritis by disrupting the clustering of PTPRS proteins
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 2D~2F
AI summary
Provided herein, inter alia, are PTPRS de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject. Also provided are methods of treating subjects with or at risk of developing extracellular matrix diseases, fibroblast-mediated diseases, or autoimmune diseases.